

**Andy Trotti, M.D.**

Professor and Director of Clinical Trials for Radiation Oncology  
Moffitt Cancer Center  
Tampa, Fla.

Dr. Trotti is a Professor and Director of Clinical Trials in Radiation Oncology at the Moffitt Cancer Center. He is recognized for his expertise in head and neck cancer and in the adverse effects of cancer treatment. His interests include improving the efficacy of radiotherapy in head and neck cancer clinical trials through integration of fractionation, advanced radiation technologies, systemic agents and biologics. He currently serves as the Co-chair of the NCI Head and Neck Steering Committee responsible for development and approval of NCI Phase II and III trials. Dr. Trotti is also Co-chair of the Head and Neck Committee for the Radiation Therapy Oncology Group (RTOG) and leads the Radiation Oncology Subcommittee of the NCCN Head and Neck Guidelines Committee. He has co-authored several landmark RTOG studies of fractionation and organ preservation. He is also recognized for his work in developing the NCI adverse event (AE) grading dictionaries (NCI-CTCAE), now widely used in oncology. Dr. Trotti is leading current NCI initiatives to develop new approaches to HPV-related head and neck cancers. He has a long standing interest in reducing the toxicity burden of cancer treatment, adverse event reporting methods, and patient reported outcomes measures.